Last update
4/12/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8
USERS' SCORE
Good
Based on 1 Review
8.4
Supplement Facts
Serving Size: 1 Tablet
Amount Per Serving
%DV
L-Lysine (from 637 mg L-Lysine Hydrochloride)
500 mg
**
Top Medical Research Studies
9
L-lysine may slow atherosclerosis
We explored how L-lysine, specifically the iNOS inhibitor N-iminoethyl-L-lysine (L-NIL), affects the progression of atherosclerosis in rabbits with high cholesterol. In our controlled study, we compared rabbits treated with L-NIL, a vehicle, or L-arginine after being fed a cholesterol-rich diet.
The results were promising; L-NIL limited the progression of atherosclerosis in the rabbits. We observed notable differences in arterial health, with less disease advancement in the L-NIL group compared to the control groups. L-arginine showed some benefits, but not to the same extent as L-NIL.
The results were promising; L-NIL limited the progression of atherosclerosis in the rabbits. We observed notable differences in arterial health, with less disease advancement in the L-NIL group compared to the control groups. L-arginine showed some benefits, but not to the same extent as L-NIL.
Read More
8
We investigated a newly developed human antibody called FAP2M21 that targets PCSK9, a protein that affects cholesterol levels. This antibody has shown excellent binding properties and can effectively inhibit the reduction of LDL cholesterol uptake in liver cells.
In experiments with mice, administering FAP2M21 significantly reduced serum LDL cholesterol levels, depending on the dosage.
While the results indicate the antibody could be a strong candidate for treating high cholesterol, further studies will be necessary to fully understand its potential in humans.
In experiments with mice, administering FAP2M21 significantly reduced serum LDL cholesterol levels, depending on the dosage.
While the results indicate the antibody could be a strong candidate for treating high cholesterol, further studies will be necessary to fully understand its potential in humans.
Read More
8
We examined the impact of L-lysine, delivered via a special method, on reducing high cholesterol. The study involved using a specific type of siRNA to target apolipoprotein B in mice.
Our findings showed a successful reduction in harmful LDL cholesterol levels in genetically modified mice, without any signs of liver damage. However, significant effects in wider populations remain unclear.
Our findings showed a successful reduction in harmful LDL cholesterol levels in genetically modified mice, without any signs of liver damage. However, significant effects in wider populations remain unclear.
Read More
Most Useful Reviews
7.5
Natural health benefits
Natural ingredients, high quality, and beneficial for health. The taste is quite pleasant.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8
- All Researches
9
L-lysine may slow atherosclerosis
We explored how L-lysine, specifically the iNOS inhibitor N-iminoethyl-L-lysine (L-NIL), affects the progression of atherosclerosis in rabbits with high cholesterol. In our controlled study, we compared rabbits treated with L-NIL, a vehicle, or L-arginine after being fed a cholesterol-rich diet.
The results were promising; L-NIL limited the progression of atherosclerosis in the rabbits. We observed notable differences in arterial health, with less disease advancement in the L-NIL group compared to the control groups. L-arginine showed some benefits, but not to the same extent as L-NIL.
The results were promising; L-NIL limited the progression of atherosclerosis in the rabbits. We observed notable differences in arterial health, with less disease advancement in the L-NIL group compared to the control groups. L-arginine showed some benefits, but not to the same extent as L-NIL.
Read More
8
We investigated a newly developed human antibody called FAP2M21 that targets PCSK9, a protein that affects cholesterol levels. This antibody has shown excellent binding properties and can effectively inhibit the reduction of LDL cholesterol uptake in liver cells.
In experiments with mice, administering FAP2M21 significantly reduced serum LDL cholesterol levels, depending on the dosage.
While the results indicate the antibody could be a strong candidate for treating high cholesterol, further studies will be necessary to fully understand its potential in humans.
In experiments with mice, administering FAP2M21 significantly reduced serum LDL cholesterol levels, depending on the dosage.
While the results indicate the antibody could be a strong candidate for treating high cholesterol, further studies will be necessary to fully understand its potential in humans.
Read More
8
We examined the impact of L-lysine, delivered via a special method, on reducing high cholesterol. The study involved using a specific type of siRNA to target apolipoprotein B in mice.
Our findings showed a successful reduction in harmful LDL cholesterol levels in genetically modified mice, without any signs of liver damage. However, significant effects in wider populations remain unclear.
Our findings showed a successful reduction in harmful LDL cholesterol levels in genetically modified mice, without any signs of liver damage. However, significant effects in wider populations remain unclear.
Read More
7
We investigated how high-protein diets and leucine supplementation impact mice, focusing on energy balance and body composition over 14 weeks.
Interestingly, we found that neither high-protein diets nor leucine supplementation influenced body weight, energy expenditure, or protein expression in the muscle.
However, plasma cholesterol levels significantly dropped in the high-protein and leucine-supplemented groups compared to those on a standard diet. Yet, there were concerns, such as increased triglycerides in the high-protein group.
Overall, while cholesterol levels showed some promise, the effects were not as widespread as we had hoped.
Interestingly, we found that neither high-protein diets nor leucine supplementation influenced body weight, energy expenditure, or protein expression in the muscle.
However, plasma cholesterol levels significantly dropped in the high-protein and leucine-supplemented groups compared to those on a standard diet. Yet, there were concerns, such as increased triglycerides in the high-protein group.
Overall, while cholesterol levels showed some promise, the effects were not as widespread as we had hoped.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Natural health benefits
Natural ingredients, high quality, and beneficial for health. The taste is quite pleasant.
Read More
Frequently Asked Questions
8
We investigated a newly developed human antibody called FAP2M21 that targets PCSK9, a protein that affects cholesterol levels. This antibody has shown excellent binding properties and can effectively inhibit the reduction of LDL cholesterol uptake in liver cells.
In experiments with mice, administering FAP2M21 significantly reduced serum LDL cholesterol levels, depending on the dosage.
While the results indicate the antibody could be a strong candidate for treating high cholesterol, further studies will be necessary to fully understand its potential in humans.
In experiments with mice, administering FAP2M21 significantly reduced serum LDL cholesterol levels, depending on the dosage.
While the results indicate the antibody could be a strong candidate for treating high cholesterol, further studies will be necessary to fully understand its potential in humans.
8
We examined the impact of L-lysine, delivered via a special method, on reducing high cholesterol. The study involved using a specific type of siRNA to target apolipoprotein B in mice.
Our findings showed a successful reduction in harmful LDL cholesterol levels in genetically modified mice, without any signs of liver damage. However, significant effects in wider populations remain unclear.
Our findings showed a successful reduction in harmful LDL cholesterol levels in genetically modified mice, without any signs of liver damage. However, significant effects in wider populations remain unclear.
9
L-lysine may slow atherosclerosis
We explored how L-lysine, specifically the iNOS inhibitor N-iminoethyl-L-lysine (L-NIL), affects the progression of atherosclerosis in rabbits with high cholesterol. In our controlled study, we compared rabbits treated with L-NIL, a vehicle, or L-arginine after being fed a cholesterol-rich diet.
The results were promising; L-NIL limited the progression of atherosclerosis in the rabbits. We observed notable differences in arterial health, with less disease advancement in the L-NIL group compared to the control groups. L-arginine showed some benefits, but not to the same extent as L-NIL.
The results were promising; L-NIL limited the progression of atherosclerosis in the rabbits. We observed notable differences in arterial health, with less disease advancement in the L-NIL group compared to the control groups. L-arginine showed some benefits, but not to the same extent as L-NIL.
7
We investigated how high-protein diets and leucine supplementation impact mice, focusing on energy balance and body composition over 14 weeks.
Interestingly, we found that neither high-protein diets nor leucine supplementation influenced body weight, energy expenditure, or protein expression in the muscle.
However, plasma cholesterol levels significantly dropped in the high-protein and leucine-supplemented groups compared to those on a standard diet. Yet, there were concerns, such as increased triglycerides in the high-protein group.
Overall, while cholesterol levels showed some promise, the effects were not as widespread as we had hoped.
Interestingly, we found that neither high-protein diets nor leucine supplementation influenced body weight, energy expenditure, or protein expression in the muscle.
However, plasma cholesterol levels significantly dropped in the high-protein and leucine-supplemented groups compared to those on a standard diet. Yet, there were concerns, such as increased triglycerides in the high-protein group.
Overall, while cholesterol levels showed some promise, the effects were not as widespread as we had hoped.
References
- Xu M, Lei G, Chen M, Wang K, Lv W, et al. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine. 2021;65:103250. 10.1016/j.ebiom.2021.103250
- Noatsch A, Petzke KJ, Millrose MK, Klaus S. Body weight and energy homeostasis was not affected in C57BL/6 mice fed high whey protein or leucine-supplemented low-fat diets. Eur J Nutr. 2011;50:479. 10.1007/s00394-010-0155-2
- Watanabe K, Harada-Shiba M, Suzuki A, Gokuden R, Kurihara R, et al. In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia. Mol Biosyst. 2009;5:1306. 10.1039/b900880b
- Behr-Roussel D, Rupin A, Simonet S, Bonhomme E, Coumailleau S, et al. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits. Circulation. 2000;102:1033. PubMed
